Lynx1 Capital Management LP 13D/13G Filings for TScan Therapeutics, Inc. (TCRX)

Lynx1 Capital Management LP 13D and 13G filings for TScan Therapeutics, Inc.:

  • Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
  • Shares have been adjusted for stock splits.
Time period
Reported
DateTime		 Transaction
Date		 Type Company
Symbol		 Filed By
Symbol		 Shares Owned
% Owned		 Shares Vs. Prev Report View
2025-02-14
09:00 am
Purchase		 2024-12-31 13G TScan Therapeutics, Inc.
TCRX		 Lynx1 Capital Management LP 5,357,347
10.900%		 132,747increase
(+2.54%)		 Filing
2023-06-02
4:56 pm
Purchase		 2023-05-31 13G TScan Therapeutics, Inc.
TCRX		 Lynx1 Capital Management LP 5,224,600
12.200%		 5,224,600increase
(New Position)		 Filing